CA3071948A1 - Mavacamten for use in the treatment of hypertrophic cardiomyopathy - Google Patents

Mavacamten for use in the treatment of hypertrophic cardiomyopathy Download PDF

Info

Publication number
CA3071948A1
CA3071948A1 CA3071948A CA3071948A CA3071948A1 CA 3071948 A1 CA3071948 A1 CA 3071948A1 CA 3071948 A CA3071948 A CA 3071948A CA 3071948 A CA3071948 A CA 3071948A CA 3071948 A1 CA3071948 A1 CA 3071948A1
Authority
CA
Canada
Prior art keywords
compound
individual
daily dose
plasma concentration
blood plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3071948A
Other languages
English (en)
French (fr)
Inventor
Marc J. SEMIGRAN
June H. LEE
Joseph Lambing
Eric Green
Marc EVANCHIK
Timothy Carlson
David Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myokardia Inc
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of CA3071948A1 publication Critical patent/CA3071948A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
CA3071948A 2017-08-04 2018-08-03 Mavacamten for use in the treatment of hypertrophic cardiomyopathy Pending CA3071948A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762541591P 2017-08-04 2017-08-04
US62/541,591 2017-08-04
US201762584537P 2017-11-10 2017-11-10
US62/584,537 2017-11-10
US201862639922P 2018-03-07 2018-03-07
US62/639,922 2018-03-07
US201862671585P 2018-05-15 2018-05-15
US62/671,585 2018-05-15
PCT/US2018/045180 WO2019028360A1 (en) 2017-08-04 2018-08-03 MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

Publications (1)

Publication Number Publication Date
CA3071948A1 true CA3071948A1 (en) 2019-02-07

Family

ID=63350605

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3071948A Pending CA3071948A1 (en) 2017-08-04 2018-08-03 Mavacamten for use in the treatment of hypertrophic cardiomyopathy

Country Status (17)

Country Link
US (5) US20200054636A1 (enExample)
EP (2) EP3661514B1 (enExample)
JP (3) JP2020529996A (enExample)
KR (2) KR20250116181A (enExample)
CN (2) CN111182901A (enExample)
AU (2) AU2018311974B2 (enExample)
CA (1) CA3071948A1 (enExample)
IL (2) IL322175A (enExample)
LT (1) LT3661514T (enExample)
MA (1) MA49760A (enExample)
MX (3) MX2020001406A (enExample)
MY (1) MY208231A (enExample)
RU (1) RU2020109345A (enExample)
SG (2) SG10202112960QA (enExample)
SM (1) SMT202500413T1 (enExample)
UY (1) UY37834A (enExample)
WO (1) WO2019028360A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI835770B (zh) 2018-01-19 2024-03-21 美商胞質動力學公司 心肌節抑制劑
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
US12187712B2 (en) 2018-06-26 2025-01-07 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2020257609A1 (en) * 2019-06-21 2020-12-24 MyoKardia, Inc. Diagnostics and treatments for cardiac disease
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
TW202134259A (zh) * 2019-11-10 2021-09-16 美商邁奧卡迪亞公司 用肌凝蛋白調節劑之治療方法
CA3165995A1 (en) * 2020-01-28 2021-08-05 Lorena KORDIC Solid state forms of mavacamten and process for preparation thereof
CA3190060A1 (en) 2020-08-28 2022-03-03 MyoKardia, Inc. Methods of treatment with myosin modulator
TW202227420A (zh) 2020-11-20 2022-07-16 大陸商江蘇恆瑞醫藥股份有限公司 三嗪二酮類衍生物、其製備方法及其在醫藥上的應用
US20240082248A1 (en) * 2021-02-01 2024-03-14 Dr. Reddy's Laboratories Limited Process for preparation of mavacamten and solid state forms thereof
EP4301760A1 (en) 2021-03-04 2024-01-10 Cytokinetics, Inc. Cardiac sarcomere inhibitors
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
PL4370116T3 (pl) * 2021-07-16 2025-04-28 Cytokinetics, Inc. Schematy dawkowania afikamtenu do leczenia obturacyjnej kardiomiopatii przerostowej
EP4404846B1 (en) * 2021-09-24 2025-10-08 Koninklijke Philips N.V. Methods and systems for generating likelihood of heart failure with preserved ejection fraction (hfpef)
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
WO2024206339A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache

Also Published As

Publication number Publication date
CN111182901A (zh) 2020-05-19
SG10202112960QA (en) 2021-12-30
US20240423981A1 (en) 2024-12-26
IL272300B1 (en) 2025-08-01
TW201916882A (zh) 2019-05-01
MX2024000348A (es) 2024-01-26
LT3661514T (lt) 2025-11-10
AU2018311974B2 (en) 2024-03-07
SMT202500413T1 (it) 2025-11-10
US20220226324A1 (en) 2022-07-21
IL322175A (en) 2025-09-01
JP2020529996A (ja) 2020-10-15
US20220313695A1 (en) 2022-10-06
AU2024203872A1 (en) 2024-06-27
JP2025020292A (ja) 2025-02-12
SG11202000549TA (en) 2020-02-27
KR20250116181A (ko) 2025-07-31
EP3661514A1 (en) 2020-06-10
AU2018311974A1 (en) 2020-02-06
IL272300A (en) 2020-03-31
CN118593507A (zh) 2024-09-06
MA49760A (fr) 2020-06-10
MX2024008096A (es) 2024-07-15
US20250213565A1 (en) 2025-07-03
WO2019028360A1 (en) 2019-02-07
EP4659806A2 (en) 2025-12-10
MX2020001406A (es) 2020-03-09
JP2023065372A (ja) 2023-05-12
UY37834A (es) 2019-02-28
MY208231A (en) 2025-04-25
EP3661514B1 (en) 2025-09-17
KR20200035973A (ko) 2020-04-06
US20200054636A1 (en) 2020-02-20
RU2020109345A (ru) 2021-09-06

Similar Documents

Publication Publication Date Title
US20250213565A1 (en) Treatment of hcm with pyrimidinedione compounds
AU2009252897B2 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
US20110166220A1 (en) Dronedarone for the prevention of permanent atrial fibrillation
CA3190060A1 (en) Methods of treatment with myosin modulator
TW202320763A (zh) 治療肥厚性心肌病之方法
KR20160095076A (ko) 주요 부정적 심혈관 사건을 감소시키기 위한 조성물 및 방법
US20110124724A1 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potasium level in the blood
JP2025172745A (ja) 肺動脈性肺高血圧症の治療方法
EP0898964A1 (en) Method for treating heart failure
HK40028703A (zh) 用於在肥厚型心肌病的治疗中使用的玛伐凯泰
MXPA05005344A (es) Formulaciones farmaceuticas liquidas que contienen 3,7-diazabiciclo [3,3,1] nonanos para tratar eventos antiarritmicos.
US20250295639A1 (en) Methods for treating heart diseases
Singh et al. Results: The results by analysis of varience revealed that wall thicknes opposite the site of infarction decreased from (mean±SD) 12.2±2.0 mm to 10.0±1.8 mm with coenzyme Q10 compared with 12.8±2.2 mm to 13.3+ 2.3
after Acute Converting Enzyme in Patients
US20130116586A1 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof for the preparation of a drug for the prevention of atrial fibrillation
HK1156502A (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
EP2431033A1 (en) Dronedarone for preventing cardiovascular hospitalization or mortality in patients with lone atrial fibrillation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928